Jennifer Brujitske, NP
Acute Care · Dearborn Heights, MINPI 1215035423
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 195 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by AbbVie at 31.9% of the total. Among acute care clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 195 payments — averaging $17.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Collegium Pharmaceutical, Inc.$394
- Scilex Pharmaceuticals Inc.$342
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$245
- Amgen$193
- Abbott$117
- plus $1K from 22 others
What the payments were for
- Food & beverage$3,395100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 62 | $1,082 |
| Collegium Pharmaceutical, Inc. | 20 | $394 |
| Scilex Pharmaceuticals Inc. | 16 | $342 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 25 | $245 |
| Amgen(2 entities) | 13 | $193 |
| Abbott | 1 | $117 |
| Boston Scientific | 6 | $96 |
| USWM, LLC | 6 | $92 |
| Vertex | 3 | $88 |
| Lilly USA, LLC | 6 | $86 |
| Almatica Pharma LLC | 4 | $73 |
| Pfizer | 4 | $69 |
| Radius Health, Inc. | 4 | $62 |
| Si-bone, Inc. | 3 | $56 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $52 |
| GRT US Holding, Inc. | 3 | $51 |
| Averitas Pharma Inc. | 2 | $39 |
| Nevro Corp. | 1 | $33 |
| Indivior Inc. | 2 | $31 |
| Orexo US, Inc. | 2 | $30 |
| SPR Therapeutics, Inc | 1 | $29 |
| Biodelivery Sciences International, Inc. | 2 | $28 |
| Medtronic | 1 | $22 |
| Biohaven Pharmaceuticals, Inc. | 1 | $22 |
| Redhill Biopharma Inc. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Pacira Pharmaceuticals Incorporated | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROCLAIM$117
How this compares
$3,395 in reported general payments places this provider in the 90th percentile of 567 acute care providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RelistorMethylnaltrexone Bromide | 24 | $53,321 |
| BelbucaBuprenorphine Hcl | 32 | $16,747 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,054 | $15,583 |
| MovantikNaloxegol Oxalate | 39 | $14,979 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 25 | $12,752 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 466 | $9,309 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 76 | $8,706 |
| Pregabalin | 375 | $8,659 |
| OxycontinOxycodone Hcl | 20 | $8,329 |
| Buprenorphine | 29 | $6,262 |
| Gabapentin | 422 | $6,223 |
| Fentanyl | 68 | $4,399 |
| Diclofenac Sodium | 23 | $3,394 |
| Lidocaine | 28 | $3,134 |
| Dexlansoprazole DrDexlansoprazole | 11 | $2,598 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $245 | $53,32124 claims |
| Collegium Pharmaceutical, Inc.Belbuca | $394 | $16,74732 claims |
| Redhill Biopharma Inc.Movantik | $18 | $14,97939 claims |
| Indivior Inc.Suboxone | $31 | $12,75225 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 567 acute care providers in Michigan.
Other acute care in Dearborn Heights
- Angela BrennanDearborn Heights$7K
- Janet WymanDetroit$103K
- Stephanie Mellon ReppenDetroit$57K
- Ashley WozniakLivonia$26K
- Julia BriggsBirch Run$16K
- Candise LovePort Huron$14K
- Janette GuertinPort Huron$14K
- Gregory AliNovi$13K
- Andrew PalmerLansing$9K
- Jennifer RutzenLansing$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.